Comparables

KPMG LLP Secures New Transfer Pricing Patent Within AI-Powered Tool

Retrieved on: 
Wednesday, February 21, 2024

KPMG LLP, the audit, tax and advisory firm, is using its newly awarded US Patent No.

Key Points: 
  • KPMG LLP, the audit, tax and advisory firm, is using its newly awarded US Patent No.
  • 11,720,842, "System and Method for Identifying Comparables" (the '842 Patent), together with artificial intelligence (AI), to help companies remain compliant and ultimately protect them from potential tax audits.
  • Transfer pricing benchmarking is a critical step in helping MNEs comply with transfer pricing rules and regulations - one that includes the review of hundreds of business descriptions and financial statements to compile a list of companies with comparable sets of data.
  • The KPMG patent enhances this historically tedious and error-prone process by leveraging AI to automate and mine the data, reducing the number of discrepancies, tax authority audits, controversies and potential fines.

Savers Value Village, Inc. Reports Third Quarter Financial Results

Retrieved on: 
Thursday, November 9, 2023

Savers Value Village, Inc. (NYSE: SVV), (the “Company”) today announced financial results for the thirteen weeks ended September 30, 2023 (the “third quarter”).

Key Points: 
  • Savers Value Village, Inc. (NYSE: SVV), (the “Company”) today announced financial results for the thirteen weeks ended September 30, 2023 (the “third quarter”).
  • For additional information on our use of non-GAAP financial measures, see “Non-GAAP Financial Measures”, “Constant Currency” and the accompanying financial tables which reconcile GAAP financial measures to these non-GAAP measures below.
  • For additional information on our use of non-GAAP financial measures, see “Non-GAAP Financial Measures” and the accompanying financial tables which reconcile GAAP financial measures to non-GAAP measures below.
  • A conference call to discuss the third quarter financial results is scheduled for today, November 9, 2023, at 4:30 p.m.

Portman Ridge Finance Corporation Announces Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Portman Ridge Finance Corporation (Nasdaq: PTMN) (the “Company” or “Portman Ridge”) announced today its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Declared stockholder distribution of $0.69 per share for the fourth quarter of 2023, payable on November 30, 2023 to stockholders of record at the close of business on November 20, 2023.
  • Including the distribution subsequent to the announcement of full year 2022 earnings results, total stockholder distributions for 2023 amount to $2.75 per share.
  • Instead, the net leverage ratio should be reviewed only in connection with such U.S. GAAP measures in analyzing Portman Ridge’s financial condition.
  • Operating results for the three months and nine ended September 30, 2023 and September 30, 2022 were as follows:

eXp World Holdings Reports Q3 2023 Results

Retrieved on: 
Thursday, November 2, 2023

BELLINGHAM, Wash., Nov. 02, 2023 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), or the “Company”, the holding company for eXp Realty®, Virbela and SUCCESS® Enterprises, today announced financial results for the third quarter ended Sept. 30, 2023.

Key Points: 
  • BELLINGHAM, Wash., Nov. 02, 2023 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), or the “Company”, the holding company for eXp Realty®, Virbela and SUCCESS® Enterprises, today announced financial results for the third quarter ended Sept. 30, 2023.
  • Appointed Bain Fellow and NPS creator Fred Reichheld to the eXp World Holdings Board of Directors on Sept. 7, 2023.
  • The Company will hold a virtual fireside chat and investor Q&A with eXp World Holdings Founder and CEO Glenn Sanford and CFO Jeff Whiteside on Thursday, Nov. 2, 2023 at 2 p.m. PT / 5 p.m.
  • The investor Q&A is open to investors, current shareholders and anyone interested in learning more about eXp World Holdings and its companies.

James Hardie Industries Announces First Quarter Fiscal Year 2024 Results

Retrieved on: 
Monday, August 7, 2023

James Hardie Industries plc (ASX: JHX; NYSE: JHX), today announced results for its first quarter ending 30 June 2023.

Key Points: 
  • James Hardie Industries plc (ASX: JHX; NYSE: JHX), today announced results for its first quarter ending 30 June 2023.
  • Our team is focused on maintaining our momentum to deliver strong financial results again in the second quarter as highlighted by our guidance range provided today.
  • Operating cash flow increased 64% to US$252.3 million in the first quarter of fiscal year 2024, driven by strong results in all three regions and significant improvement in working capital.
  • Guidance for the second quarter of fiscal year 2024; we expect:
    For the full year FY24, we expect to spend a total of approximately US$550 million in capital expenditures.

James Hardie Industries Announces Fourth Quarter And Fiscal Year 2023 Results

Retrieved on: 
Monday, May 15, 2023

James Hardie Industries plc (ASX: JHX; NYSE: JHX), today announced results for its fourth quarter and full year ending 31 March 2023.

Key Points: 
  • James Hardie Industries plc (ASX: JHX; NYSE: JHX), today announced results for its fourth quarter and full year ending 31 March 2023.
  • I believe our fourth quarter results are a proof point that we are effectively managing through this cycle.
  • In our largest market, North America, we expect our addressable market to decrease between 14% and 19% in fiscal year 2024 versus fiscal year 2023.
  • James Hardie’s guidance is based on current estimates and assumptions and is subject to several known and unknown uncertainties and risks.

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates

Retrieved on: 
Thursday, May 11, 2023

SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates.

Key Points: 
  • SAN DIEGO, May 11, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the three months ended March 31, 2023 and highlighted recent corporate updates.
  • First quarter 2023 net product sales grew 26% to $29.6 million, compared to the first quarter of 2022.
  • Net product sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three months ended March 31, 2023 was $3.5 million.
  • Net product sales of APONVIE for the three months ended March 31, 2023 were $0.3 million.

Logan Ridge Finance Corporation Announces First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023

NEW YORK, May 10, 2023 (GLOBE NEWSWIRE) -- Logan Ridge Finance Corporation (“Logan Ridge”, “LRFC”, “Company”, “we”, “us” or “our”) (Nasdaq: LRFC) announced today its financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Reports a Strong First Quarter with Net Investment Income of $0.40 Per Share, a 69% Increase from the Prior Quarter and its Third Consecutive Quarter of Positive Net Investment Income
    Announces Distribution of $0.22 Per Share for the Second Quarter of 2023, a 22% Increase as Compared to $0.18 Per Share during the First Quarter of 2023
    NEW YORK, May 10, 2023 (GLOBE NEWSWIRE) -- Logan Ridge Finance Corporation (“Logan Ridge”, “LRFC”, “Company”, “we”, “us” or “our”) (Nasdaq: LRFC) announced today its financial results for the first quarter ended March 31, 2023.
  • Net asset value decreased to $34.63 per share as of March 31, 2023 from $35.04 per share in the prior quarter.
  • As of March 31, 2023, our portfolio consisted of investments in 59 portfolio companies with a fair value of approximately $203.3 million.
  • On May 9, 2023, the Company’s Board of Directors approved a distribution of $0.22 per share payable on May 31, 2023 to stockholders of record as of May 22, 2023.

eXp World Holdings Reports Q1 2023 Results

Retrieved on: 
Tuesday, May 2, 2023

BELLINGHAM, Wash., May 02, 2023 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), (or the “Company”), the holding company for eXp Realty®, Virbela and SUCCESS® Enterprises, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • BELLINGHAM, Wash., May 02, 2023 (GLOBE NEWSWIRE) -- eXp World Holdings, Inc. (Nasdaq: EXPI), (or the “Company”), the holding company for eXp Realty®, Virbela and SUCCESS® Enterprises, today announced financial results for the first quarter ended March 31, 2023.
  • "Our International Realty segment had a record revenue quarter with 52% year-over-year growth, and we remain focused on driving durable, profitable growth across the eXp World Holdings portfolio."
  • The Company will hold a virtual fireside chat and investor Q&A with eXp World Holdings Founder and CEO Glenn Sanford and CFO Jeff Whiteside on Tuesday, May 2, 2023 at 2 p.m. PT / 5 p.m.
  • The investor Q&A is open to investors, current shareholders and anyone interested in learning more about eXp World Holdings and its companies.

Cansortium Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Monday, May 1, 2023

In addition, our exit from Michigan last August enabled us to strategically reallocate capital and sharpen focus on our core operations.

Key Points: 
  • In addition, our exit from Michigan last August enabled us to strategically reallocate capital and sharpen focus on our core operations.
  • Q4 2022 Financial Highlights (vs. Q4 2021)
    Revenue increased 28% to $23.5 million compared to $18.3 million.
  • FY 2022 Financial Highlights (vs. FY 2021)
    Revenue increased 34% to $87.7 million compared to $65.4 million.
  • In Pennsylvania, Cansortium recently began the expansion of its Hanover dispensary to maximize the store's capacity for patients.